Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single-center, retrospective, longitudinal cohort study.
artificial intelligence-analysis
thymic epithelial tumor
tumor-infiltrating lymphocyte
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
19
07
2023
accepted:
16
08
2023
medline:
27
10
2023
pubmed:
7
9
2023
entrez:
7
9
2023
Statut:
ppublish
Résumé
Thymic epithelial tumors (TET) are rare malignancies and lack well-defined biomarkers for neoadjuvant therapy. This study aimed to evaluate the clinical utility of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in TET. Patients initially diagnosed with unresectable thymoma or thymic carcinoma who underwent neoadjuvant therapy between January 2004 and December 2021 formed our study population. Hematoxylin and eosin-stained sections from the initial biopsy and surgery were analyzed using an AI-powered spatial TIL analyzer. Intratumoral TIL (iTIL) and stromal TIL (sTIL) were quantified and their immune phenotype (IP) was identified. Thirty-five patients were included in this study. The proportion of patients with partial response to neoadjuvant therapy was higher in the group with nondesert IP in preneoadjuvant biopsy (63.6% vs. 17.6%, p = 0.038). A significant increase in both iTIL (median 22.18/mm Nondesert IP in initial biopsy was associated with a better response to neoadjuvant therapy. Increased infiltration of both iTIL and sTIL in surgical specimens were associated with longer OS in patients with TET who underwent resection followed by neoadjuvant therapy.
Sections du résumé
BACKGROUND
Thymic epithelial tumors (TET) are rare malignancies and lack well-defined biomarkers for neoadjuvant therapy. This study aimed to evaluate the clinical utility of artificial intelligence (AI)-powered tumor-infiltrating lymphocyte (TIL) analysis in TET.
METHODS
Patients initially diagnosed with unresectable thymoma or thymic carcinoma who underwent neoadjuvant therapy between January 2004 and December 2021 formed our study population. Hematoxylin and eosin-stained sections from the initial biopsy and surgery were analyzed using an AI-powered spatial TIL analyzer. Intratumoral TIL (iTIL) and stromal TIL (sTIL) were quantified and their immune phenotype (IP) was identified.
RESULTS
Thirty-five patients were included in this study. The proportion of patients with partial response to neoadjuvant therapy was higher in the group with nondesert IP in preneoadjuvant biopsy (63.6% vs. 17.6%, p = 0.038). A significant increase in both iTIL (median 22.18/mm
CONCLUSIONS
Nondesert IP in initial biopsy was associated with a better response to neoadjuvant therapy. Increased infiltration of both iTIL and sTIL in surgical specimens were associated with longer OS in patients with TET who underwent resection followed by neoadjuvant therapy.
Identifiants
pubmed: 37675597
doi: 10.1111/1759-7714.15089
pmc: PMC10599973
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3001-3011Informations de copyright
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Nat Commun. 2022 Sep 17;13(1):5463
pubmed: 36115836
Mod Pathol. 2021 Dec;34(12):2130-2140
pubmed: 34218258
Semin Diagn Pathol. 2022 Mar;39(2):99-104
pubmed: 34147302
Thorac Cancer. 2023 Oct;14(30):3001-3011
pubmed: 37675597
Ann Thorac Surg. 2003 Sep;76(3):878-84; discussion 884-5
pubmed: 12963221
J Thorac Cardiovasc Surg. 2015 Jan;149(1):95-100, 101.e1-2
pubmed: 25524678
Lancet Oncol. 2018 Mar;19(3):347-355
pubmed: 29395863
Cancer. 1991 Aug 15;68(4):706-13
pubmed: 1855170
J Thorac Oncol. 2011 Jul;6(7 Suppl 3):S1749-55
pubmed: 21847058
BMC Genomics. 2007 Sep 03;8:305
pubmed: 17764580
J Thorac Oncol. 2017 Feb;12(2):354-367
pubmed: 27666658
Int J Cancer. 2003 Jul 1;105(4):546-51
pubmed: 12712448
Ann Oncol. 2019 Aug 1;30(8):1183-1184
pubmed: 31287498
Am J Cancer Res. 2022 May 15;12(5):2387-2396
pubmed: 35693087
Nat Rev Immunol. 2020 Apr;20(4):239-253
pubmed: 31804611
J Thorac Cardiovasc Surg. 1993 Sep;106(3):543-9
pubmed: 8361199
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
J Clin Oncol. 2022 Jun 10;40(17):1916-1928
pubmed: 35271299
J Clin Oncol. 2019 Aug 20;37(24):2162-2170
pubmed: 29906252
Lung Cancer. 2004 Jun;44(3):369-79
pubmed: 15140551
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Thorac Cardiovasc Surg. 2014 Jan;147(1):36-44, 46.e1
pubmed: 24139613
Cancer Treat Rev. 2017 Jun;57:8-15
pubmed: 28525810
J Thorac Oncol. 2009 Jan;4(1):119-26
pubmed: 19096319
J Thorac Oncol. 2009 Jul;4(7):911-9
pubmed: 19557895
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Thorac Oncol. 2008 Mar;3(3):270-6
pubmed: 18317070
Br J Cancer. 2010 Jun 29;103(1):6-11
pubmed: 20551960
Cancer Cell. 2018 Feb 12;33(2):244-258.e10
pubmed: 29438696
Ann Oncol. 2015 Sep;26 Suppl 5:v40-55
pubmed: 26314779
Clin Cancer Res. 2017 Aug 15;23(16):4855-4864
pubmed: 28400429
Nat Genet. 2014 Aug;46(8):844-9
pubmed: 24974848
Ann Thorac Surg. 2004 May;77(5):1860-9
pubmed: 15111216
J Surg Oncol. 1993 Nov;54(3):180-3
pubmed: 8412175
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259